[Uniform classification of the pachychoroid spectrum disorders].

Einheitliche Klassifikation des pachychorioidalen Krankheitsspektrums.
Central serous chorioretinopathy Focal choroidal excavation Pachychoroid neovasculopathy Pachychoroid pigment epitheliopathy Peripapillary pachychoroid syndrome

Journal

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
ISSN: 1433-0423
Titre abrégé: Ophthalmologe
Pays: Germany
ID NLM: 9206148

Informations de publication

Date de publication:
Aug 2021
Historique:
accepted: 19 03 2021
pubmed: 27 4 2021
medline: 10 8 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Pachychoroid spectrum disorders are characterized by a thickening of the choroid. The spectrum includes pachychoroid pigment epitheliopathy (PPE), central serous chorioretinopathy (CCS), pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy (PCV)/aneurysmal type 1 choroidal neovascularization (ACNV-1), focal choroidal excavation (FCE) and peripapillary pachychoroid syndrome (PPS). If the choroid is thickened and there is a pathological alteration in the retinal pigment epithelium, the diagnosis is PPE; if the thickened choroid is accompanied by subretinal fluid, the diagnosis is CCS; if choroidal neovascularization is present, the diagnosis is PNV; if accompanied by aneurysms, the diagnosis is ACNV‑1. The PPE, CCS, PNV and ACNV‑1 were formerly regarded as independent disease entities but can be classified into four forms of a single disease family, pachychoroid macular disease. Die pachychorioidalen Erkrankungen sind alle durch eine Verdickung der Aderhaut gekennzeichnet. Die Gruppe umfasst die folgenden Krankheitsgruppen: pachychorioidale Pigmentepitheliopathie (PPE), Chorioretinopathia centralis serosa (CCS), pachychorioidale Neovaskulopathie (PNV), polypoidale chorioidale Vaskulopathie (PCV)/aneurysmatische chorioidale Neovaskularisation Typ 1 (ACNV‑1), fokale chorioidale Exkavation (FCE) und peripapilläres pachychorioidales Syndrom (PPS). Wenn bei verdickter Aderhaut zusätzlich eine Veränderung des retinalen Pigmentepithels vorliegt, lautet die Diagnose PPE; wenn die verdickte Aderhaut von subretinaler Flüssigkeit begleitet ist, lautet die Diagnose CCS; wenn eine chorioidale Neovaskularisation vorliegt, lautet die Diagnose PNV; wenn sie von Aneurysmen begleitet ist, lautet die Diagnose ACNV‑1. PPE, CCS, PNV und ACNV‑1 wurden als unabhängige Krankheitsentitäten angesehen, lassen sich aber als 4 Formen einer einzigen Krankheitsfamilie, der „pachychorioidalen Makulaerkrankung“, klassifizieren.

Autres résumés

Type: Publisher (ger)
Die pachychorioidalen Erkrankungen sind alle durch eine Verdickung der Aderhaut gekennzeichnet. Die Gruppe umfasst die folgenden Krankheitsgruppen: pachychorioidale Pigmentepitheliopathie (PPE), Chorioretinopathia centralis serosa (CCS), pachychorioidale Neovaskulopathie (PNV), polypoidale chorioidale Vaskulopathie (PCV)/aneurysmatische chorioidale Neovaskularisation Typ 1 (ACNV‑1), fokale chorioidale Exkavation (FCE) und peripapilläres pachychorioidales Syndrom (PPS). Wenn bei verdickter Aderhaut zusätzlich eine Veränderung des retinalen Pigmentepithels vorliegt, lautet die Diagnose PPE; wenn die verdickte Aderhaut von subretinaler Flüssigkeit begleitet ist, lautet die Diagnose CCS; wenn eine chorioidale Neovaskularisation vorliegt, lautet die Diagnose PNV; wenn sie von Aneurysmen begleitet ist, lautet die Diagnose ACNV‑1. PPE, CCS, PNV und ACNV‑1 wurden als unabhängige Krankheitsentitäten angesehen, lassen sich aber als 4 Formen einer einzigen Krankheitsfamilie, der „pachychorioidalen Makulaerkrankung“, klassifizieren.

Identifiants

pubmed: 33900429
doi: 10.1007/s00347-021-01379-4
pii: 10.1007/s00347-021-01379-4
doi:

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

865-878

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Références

Ryan SJ (2006) Retina, 4. Aufl. Bd. 1. Elsevier Mosby, Philadelphia
Usui S, Ikuno Y, Akiba M, Maruko I, Sekiryu T, Nishida K, Iida T (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci 53:2300–2307
pubmed: 22427554 pmcid: 22427554 doi: 10.1167/iovs.11-8383
Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672
pubmed: 23751942 doi: 10.1097/IAE.0b013e3182953df4
Dansingani KK, Balaratnasingam C, Naysan J, Freund KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36:499–516
pubmed: 26335436 doi: 10.1097/IAE.0000000000000742
Cheung CMG, Lee WK, Koizumi H et al (2019) Pachychoroid disease. Eye (Lond) 33:14–33
doi: 10.1038/s41433-018-0158-4
Ruiz-Medrano J, Flores-Moreno I, Peña-García P, Montero JA, Duker JS, Ruiz-Moreno JM (2014) Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 55:3532–3542
pubmed: 24845638 doi: 10.1167/iovs.14-13868
Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3:1013–1015
pubmed: 31810570 doi: 10.1016/j.oret.2019.08.002
Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51:2173–2176
pubmed: 19892874 doi: 10.1167/iovs.09-4383
Coskun E, Okumus S, Gürler B et al (2014) Choroidal thickness in healthy Turkish subjects. Turk J Med Sci 44:56–61
pubmed: 25558559 doi: 10.3906/sag-1211-43
Kim JH, Kang SW, Kim JR, Kim SJ (2013) Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Eye (Lond) 27:809–815
doi: 10.1038/eye.2013.78
Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496–500
pubmed: 18639219 doi: 10.1016/j.ajo.2008.05.032
Ferrara D, Mohler KJ, Waheed N et al (2014) En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy. Ophthalmology 121:719–726
pubmed: 24289918 doi: 10.1016/j.ophtha.2013.10.014
Yang L, Jonas JB, Wei W (2013) Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 91:358–362
doi: 10.1111/aos.12059
Azar G, Wolff B, Mauget-Faÿsse M, Rispoli M, Savastano MC, Lumbroso B (2017) Pachychoroid neovasculopathy: aspect on optical coherence tomography angiography. Acta Ophthalmol 95:421–427
pubmed: 27597633 doi: 10.1111/aos.13221
Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110
pubmed: 7542796 doi: 10.1097/00006982-199515020-00003
Yannuzzi LA (2011) Indocyanine green angiography: a perspective on use in the clinical setting. Am J Ophthalmol 151:745–751
pubmed: 21501704 doi: 10.1016/j.ajo.2011.01.043
Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M (2018) Indocyanine green angiography of pachychoroid pigment epitheliopathy. Retina 38:1668–1674
pubmed: 28723851 doi: 10.1097/IAE.0000000000001773
Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103126
doi: 10.1016/j.survophthal.2012.07.004
Gal-Or O, Dansingani KK, Sebrow D, Dolz-Marco R, Freund KB (2018) Inner choroidal flow signal attenuation in pachychoroid disease: optical coherence tomography angiography. Retina 38:1984–1992
pubmed: 29384997 doi: 10.1097/IAE.0000000000002051
Venkatesh P, Takkar B, Temkar S (2018) Clinical manifestations of pachychoroid may be secondary to pachysclera and increased scleral rigidity. Med Hypotheses 113:72–73
pubmed: 29523299 doi: 10.1016/j.mehy.2018.02.024
Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F (2015) Pachychoroid: an inherited condition? Retina 35:10–16
pubmed: 25046398 doi: 10.1097/IAE.0000000000000287
Shah VS, Manayath FGJ, Saravanan VR, Shah PK, Prabhu V, Karandikar SS, Kalpana N (2017) PCV and CSR: diseases of the same spectrum?
Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243–54.e2
pubmed: 26319161 doi: 10.1016/j.ajo.2015.08.028
Pang CE, Freund KB (2014) Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis. Invest Ophthalmol Vis Sci 55:5252
pubmed: 25149971 doi: 10.1167/iovs.14-14959
Wykrota A, Löw U, Fries FF, Seitz B, Abdin AD (2020) Unilaterale makuläre Pigmentepithelunregelmäßigkeiten bei einem 38-jährigen Patienten – „Akute retinale Pigmentepitheliitis“. Klin Monatsbl Augenheilkd. https://doi.org/10.1055/a-1241-4521
doi: 10.1055/a-1241-4521 pubmed: 33036057
Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, Mrejen S, Freund KB (2014) Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol 3:111115
Lange C, Treumer F, Bertram B, Feltgen N, Hoerauf H, Pauleikhoff D, Roider J (2019) Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS). Ophthalmologe 116:10–20
doi: 10.1007/s00347-018-0809-7
Liegl R, Ulbig MW (2014) Central serous chorioretinopathy. Ophthalmologica 232:65–76
pubmed: 24776999 doi: 10.1159/000360014
Baraki H, Feltgen N, Roider J, Hoerauf H, Klatt C (2010) Chorioretinopathia centralis serosa (CCS). Ophthalmologe 107:479–492
pubmed: 20454897 doi: 10.1007/s00347-010-2154-3
Garg SP, Dada T, Talwar D, Biswas NR (1997) Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 81:962–964
pubmed: 9505819 pmcid: 1722041 doi: 10.1136/bjo.81.11.962
Eom Y, Oh J, Kim SW, Huh K (2012) Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol 26:260–264
pubmed: 22870024 pmcid: 3408530 doi: 10.3341/kjo.2012.26.4.260
de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570
pubmed: 25439433 doi: 10.1016/j.ophtha.2014.09.026
Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867
pubmed: 24665005 pmcid: 4215937 doi: 10.1002/humu.22551
Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747
pubmed: 7777273 doi: 10.1016/S0161-6420(95)30960-8
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118
pubmed: 26026923 doi: 10.1016/j.preteyeres.2015.05.003
Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712
pubmed: 24100708 doi: 10.1097/IAE.0000000000000001
Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351
pubmed: 19830441 doi: 10.1007/s00417-009-1212-5
Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112:1057–1062
pubmed: 8053819 doi: 10.1001/archopht.1994.01090200063023
Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897
pubmed: 25563727 doi: 10.1007/s00417-014-2899-5
Bonini Filho MA, de Carlo TE, Ferrara D et al (2015) Association of choroidal 642 neovascularization and central serous chorioretinopathy with optical coherence 643 tomography angiography. JAMA Ophthalmol 133:899–906
pubmed: 25996386 doi: 10.1001/jamaophthalmol.2015.1320
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294–303
pubmed: 31982075 doi: 10.1016/S0140-6736(19)32981-2
Frankel D, Suffo S, Seitz B, Abdin AD (2020) Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. https://doi.org/10.1177/1120672120952648
doi: 10.1177/1120672120952648
Bousquet E, Dhundass M, Lejoyeux R, Shinojima A, Krivosic V, Mrejen S, Gaudric A, Tadayoni R (2019) Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy. Am J Ophthalmol 198:80–87
pubmed: 30308202 doi: 10.1016/j.ajo.2018.09.034
Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP (2014) Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 111:173–180
pubmed: 24510173 doi: 10.1007/s00347-013-3001-0
Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 3:555–561
doi: 10.1016/j.ophtha.2014.09.034
Funk S, Fulga R, Klabe K, Breyer D, Seitz B, Langenbucher A, Kaymak H (2021) Nanosecond laser treatment in chorioretinopathia centralis serosa without RPE defects: a retrospective case series. Klin Monatsbl Augenheilkd 238(1):60–66. https://doi.org/10.1055/a-0999-5542
doi: 10.1055/a-0999-5542 pubmed: 31600817
Kaymak H, Funk S, Fricke A et al (2020) Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium. Int J Retin Vitr 6:11
doi: 10.1186/s40942-020-00214-3
Akkaya S (2018) Spectrum of pachychoroid diseases. Int Ophthalmol 38:2239–2246
pubmed: 28766279 doi: 10.1007/s10792-017-0666-4
Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9
pubmed: 25158945 doi: 10.1097/IAE.0000000000000331
Schworm B, Luft N, Keidel LF et al (2020) Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to aflibercept. Sci Rep 10:8439
pubmed: 32439930 pmcid: 7242401 doi: 10.1038/s41598-020-65370-w
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8
pubmed: 1693009 doi: 10.1097/00006982-199010010-00001
Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB (2018) Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of ‘expanded spectra’—a review. J Clin Exp Ophthalmol 46:189–200
doi: 10.1111/ceo.13114
Wong CW, Yanagi Y, Lee WK et al (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139
pubmed: 27094371 doi: 10.1016/j.preteyeres.2016.04.002
Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB (2016) Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina 36:73–82
doi: 10.1097/IAE.0000000000001346
Lin WY, Yang SC, Chen SJ, Tsai CL, Du SZ, Lim TH (2015) Automatic segmentation of polypoidal choroidal vasculopathy from indocyanine green angiography using spatial and temporal patterns. Transl Vis Sci Technol 4:7
pubmed: 25806144 pmcid: 4364496 doi: 10.1167/tvst.4.2.7
Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957
doi: 10.1038/eye.2014.134
Padron-Perez N, Arias L, Rubio M et al (2018) Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci 59:1119–1124
pubmed: 29490349 doi: 10.1167/iovs.17-22144
Chung H, Byeon SH, Freund KB (2017) Focal choroidal excavation and its association with pachychoroid spectrum disorders: a review of the literature and multimodal imaging findings. Retina 37:199–221
pubmed: 27749784 doi: 10.1097/IAE.0000000000001345
Obata R, Takahashi H, Ueta T, Yuda K, Kure K, Yanagi Y (2013) Tomographic and angiographic characteristics of eyes with macular focal choroidal excavation. Retina 33:1201–1210
pubmed: 23514801 doi: 10.1097/IAE.0b013e31827b6452
Hoogmartens C, Stanzel BV (2020) Akute makuläre Neuroretinopathie bei einer 13jährigen Patientin mit fokaler choroidaler Exkavation und Pachychoroid. Ophthalmologe 117:791–797
pubmed: 31562562 doi: 10.1007/s00347-019-00974-w
Phasukkijwatana N, Freund KB, Dolz-Marco R et al (2018) Peripapillary pachychoroid syndrome. Retina 9:1652–1667
doi: 10.1097/IAE.0000000000001907
Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829–1837
pubmed: 22850219 doi: 10.1097/IAE.0b013e3182680a66
Ahuja RM, Downes SM, Stanga PE et al (2001) Polypoidal choroidal vasculopathy and central serous chorioretinopathy. Ophthalmology 108:1009–1010
pubmed: 11382610 doi: 10.1016/S0161-6420(00)00614-X
Koh A, Ahuja R, Downes S, Bird A (1999) Polypoidal choroidal vasculopathy in patients with chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 40:5958
Perkins SL, Kim JE, Pollack JS, Merrill PT (2002) Clinical characteristics of central serous chorioretinopathy in women. Ophthalmology 109:262–266
pubmed: 11825806 doi: 10.1016/S0161-6420(01)00951-4
Spaide RF (2020) The ambiguity of pachychoroid. Retina. https://doi.org/10.1097/IAE.0000000000003057
doi: 10.1097/IAE.0000000000003057 pubmed: 33348085 pmcid: 7103566

Auteurs

Alaa Din Abdin (AD)

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66421, Homburg/Saar, Deutschland. alaadin.abdin@uks.eu.

Shady Suffo (S)

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66421, Homburg/Saar, Deutschland.

Fabian N Fries (FN)

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66421, Homburg/Saar, Deutschland.

Hakan Kaymak (H)

Internationale Innovative Ophthalmochirurgie (I. I. O.), 40549, Düsseldorf, Deutschland.

Berthold Seitz (B)

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66421, Homburg/Saar, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH